Clinical Trial

A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2025 (before its estimated April 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
Trial Details
NCT Number NCT06850480
Lead Sponsor Livzon Pharmaceutical Group Inc.
Conditions Reflux Esophagitis (RE)
Enrollment 356 participants
Start Date 2024-12-05
Primary Completion 2025-04-15 (estimated)
Study Completion 2025-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-27